# A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

> **NCT00144053** · PHASE3 · COMPLETED · sponsor: **West Japan Thoracic Oncology Group** · enrollment: 450 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Cisplatin+Vindesine+MMC/ concurrent radiation
- **DRUG:** Irinotecan+Carboplatin/concurrent radiation
- **DRUG:** Paclitaxel+Carboplatin/concurrent radiation

## Key facts

- **NCT ID:** NCT00144053
- **Lead sponsor:** West Japan Thoracic Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 450 (—)
- **Last updated:** 2006-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144053, "A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00144053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*